Learn about TRIO in ~90 Seconds


CRO Oncology Experts

CRO Oncology Experts

Oncology is not just another indication in our portfolio. It’s the only one, and it’s our specialty. We understand the therapeutic area, the challenges and the complexities associated with expediting cancer clinical trials. That’s why TRIO Operations is supported by a team of global Key Opinion Leaders who provide input on trial design and execution, promote our trials to accelerate enrollment and critically analyze results.

Our Track record of success

Track Record of Success

All of our phase III trials have completed enrollment on time, if not earlier! Four of the registration trials we’ve conducted have led to approval, changing the lives of countless cancer patients worldwide. We have also developed our expertise in early phase trials, including First-In Human (FIH) studies. This has propelled us to become protagonists across the full drug development pathway.

An A-Team partner

An “A-Team” Partnering with You

We have world-class leadership and operation teams whose main goal is to optimize trial start-up and execution—all while maintaining high-quality and effective collaboration with our Sponsors and Investigators. Over the decades, we’ve built a reputation for long-term partnerships with our customers that are based on success and trust.

Investigator Network

Investigator Network

We’re proud of having built a Top Tier Network of over 500 highly experienced, sought-after investigational sites, spanning more than 20 countries and four continents. Our network has been paramount to our successes.

TRIO Key Figures


Phase III trials enrolled on time


Practice-changing trials (and counting)


Patients enrolled


Database locks on time over the last 2 years


Sponsors that trusted in TRIO as their clinical research partner


Global Hubs

Investigator Network
Trio Locations

The Latest From Trio

NATALEE (TRIO033) Phase III trial demonstrates ribociclib significantly reduces the risk of recurrence for patients with early breast cancer, at interim analysis

Translational Research In Oncology (TRIO) today announced positive topline results from NATALEE (TRIO033), a Novartis sponsored Phase III trial of ribociclib plus endocrine therapy (ET)…

Read More >
TRIO is proud to be on the 2023 list of Canada’s Top Small and Medium Employers for the 3rd year in a row

For a third year in a row! We are very proud to be on a list with a great group of employers. Our people are…

Read More >
TRIO ranks 4th among Uruguay’s best workplaces in 2023 as chosen by Great Place to Work™

After obtaining the Great Place to Work® certification in 2022, we are happy to announce that TRIO Uruguay has been ranked fourth among Uruguay’s best…

Read More >

Find Out More

Our Sponsors


At TRIO, we work as your partner to deliver quality oncology trials internationally, accelerate your drug development and improve the lives of patients with cancer. Learn how TRIO can support your oncology clinical study.

Doctor holding a patient's hand


Since our inception in 1997, TRIO has been at the forefront of clinical cancer research. We have built deep relationships with highly experienced, sought-after Investigators who are pivotal to our success and recognized for their contributions.